First episode psychosis refers to the point at which a person experiences psychotic symptoms for the first time in their life. These symptoms can include hallucinations, delusions, disorganized thinking or major changes in behavior and functioning. FEP is not a single diagnosis. It can occur in schizophrenia-spectrum disorders, bipolar disorder, severe depression and several medical or substance-related conditions. Because early treatment is linked to better long-term outcomes, knowing how often FEP occurs is essential for planning specialized clinics, staffing early-intervention programs and directing public-health resources.

The researchers focus on U.S. claims data, enormous digital records generated when patients receive medical care and providers submit bills to insurers. These databases can include diagnostic codes, procedure codes, prescription information, dates of service and details about emergency, inpatient and outpatient treatment. Unlike traditional epidemiological surveys, claims datasets can cover millions of people and make it possible to study patterns across large geographic areas. Their scale, however, does not automatically make their estimates precise.

The central challenge is that a billing code is not the same as a clinical assessment. A code for psychosis may indicate a confirmed diagnosis, a suspected condition, a historical problem or a provisional label assigned during an emergency evaluation. Claims data also rarely contain the complete clinical narrative needed to determine whether symptoms truly represent a person’s first psychotic episode. A patient may have received care in another health system, paid out of pocket, changed insurers or carried an earlier diagnosis that is invisible in the database being studied.

Even the definition of “incidence” can vary. Some researchers count a first-ever psychosis-related diagnosis, while others count a first hospitalization, a first emergency-department visit or the first appearance of a relevant code after a period without documented care. These approaches can produce different numbers from the same underlying population. A study requiring a long “clean period”—a span of time with no previous psychosis-related claims—may reduce the likelihood of counting established cases as new, but it can also exclude people whose earlier treatment occurred outside the available records.

Age, sex, insurance type and geography can further influence the apparent rate of FEP. Young adults may be more likely to encounter emergency services, while people in rural areas may face limited access to psychiatrists and specialized programs. Differences in insurance coverage can determine which services generate observable claims. If researchers compare estimates without accounting for these factors, they may mistake variations in detection or access for genuine differences in disease occurrence.

The study’s call for standardization points toward a more consistent technical framework. Researchers need to specify which diagnostic codes qualify as psychosis, whether substance-induced and medically caused episodes are included, how long a person must remain free of prior claims to be considered a new case, and which healthcare settings are examined. They also need to define the population denominator—the number of people considered at risk—and explain how individuals with incomplete enrollment or interrupted insurance coverage are handled.

Validation is another crucial step. Claims-based algorithms should be compared with detailed chart reviews, clinical registries or structured assessments to determine how accurately they identify genuine FEP. Two statistical measures are especially important: sensitivity, or the ability to capture true cases, and positive predictive value, or the proportion of algorithm-identified cases that are confirmed after review. An algorithm with high sensitivity may find more possible cases but also produce more false positives; one with high specificity may miss people who received vague or inconsistent coding.

Standardized methods could make FEP estimates more comparable across states, insurers and research teams. That would help scientists detect real trends rather than methodological noise and could reveal whether early psychosis services are reaching the populations most in need. More reliable estimates could also strengthen efforts to investigate racial, socioeconomic and regional disparities, provided that claims data are interpreted carefully and not treated as a complete substitute for clinical information.

The message from the research is not that U.S. claims databases are unusable. On the contrary, their breadth makes them one of the most powerful tools available for studying mental-health care at scale. But their value depends on transparent definitions, validated case-finding methods and clear reporting standards. As health systems increasingly rely on administrative data and automated analytics, agreeing on what counts as a new case of psychosis may be the difference between a map that reveals a public-health crisis and one that merely reflects the quirks of the billing system.

Subject of Research: Estimating first episode psychosis incidence rates using U.S. claims data

Article Title: Estimating first episode psychosis (FEP) incidence rates using U.S. claims data: a need for standardization

Article References: Seiber, E.E., Sridhar, S., Hasenstab, K.A. et al. “Estimating first episode psychosis (FEP) incidence rates using U.S. claims data: a need for standardization.” Schizophrenia (2026). https://doi.org/10.1038/s41537-026-00793-4

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00793-4

Keywords: First episode psychosis, FEP, incidence rates, U.S. claims data, schizophrenia, mental health, epidemiology, healthcare data, standardization

The global tally in 2021 alone revealed an alarming 444 million new cases of mental disorders, coupled with over 155 million DALYs, indicators of the vast human suffering and functional impairments attributable to these conditions. Notably, the study identified a pronounced upward trend in both the age-standardized incidence rate (ASIR) and age-standardized DALY rate (ASR), with increases of approximately 15.2% and 17.3%, respectively, over the three decades reviewed. Such trends not only reflect heightened recognition and diagnosis of mental disorders but also the growing public health impact these diseases exert worldwide.

Regional disparities emerged strongly from the analysis, with Central Sub-Saharan Africa exhibiting the highest ASIR — nearly triple that observed in East Asia, the region with the lowest rates. Contrarily, Australia reported the highest ASR, highlighting significant geographic variability in disease burden and healthcare outcomes. On a national scale, countries such as Greenland, Greece, the United States, and Australia registered the highest DALY rates, indicating concentrated areas where mental health infrastructure and intervention may require urgent reinforcement.

The socio-demographic index (SDI), a composite measure incorporating income, education, and fertility rates, profoundly influenced mental disorder burdens. Interestingly, while all SDI quintiles except East Asia experienced increased incidence rates during the COVID-19 pandemic period (2019–2021), the data underscore the pandemic’s differential impact on mental health globally. These findings provide crucial insight into how social determinants and regional dynamics intersect with disease patterns, emphasizing the need for tailored public health strategies.

Gender-based analysis revealed that females consistently bore a higher burden of mental disorders as measured by age-standardized rates. This disparity illuminates complex socio-cultural, biological, and psychological factors contributing to women’s elevated vulnerability. Understanding these dynamics can help shape gender-sensitive mental health policies and ensure equitable access to care and resources.

Delving deeper into specific mental disorder subtypes, major depressive disorder and anxiety disorders emerged as the leading contributors to the mental health burden, possessing the highest age-standardized rates worldwide. Major depressive disorder, in particular, ranked first in the burden across 13 of 21 global regions, reaffirming its role as a profound public health challenge. Notably, anxiety disorders also exhibited the most significant increase in DALYs over time, highlighting their growing societal impact.

Intriguingly, the overall upward trend in DALYs was not uniform across all mental disorder subtypes. This heterogeneity suggests variations in disease detection, treatment efficacy, and possibly differing etiological factors. These nuances are critical for guiding resource allocation and prioritizing disorder-specific interventions that can more effectively mitigate the global mental health burden.

At the heart of these findings is the recognition that mental disorders represent an escalating global health crisis with widespread implications for societies and healthcare systems. The study’s longitudinal design, encompassing 31 years of data, enables an appreciation not only of current disease magnitude but also of evolving trends, enabling policymakers and healthcare providers to anticipate future challenges with greater precision.

The COVID-19 pandemic’s role as a catalyst exacerbating mental health issues is particularly salient. Social isolation, economic uncertainty, and disruption of health services during this period likely intensified mental health struggles worldwide. The pandemic thus underscores the urgency for integrating mental health support into broader emergency preparedness and response frameworks.

Given these insights, the authors advocate for comprehensive mental health strategies encompassing knowledge dissemination, prevention initiatives, and the development of tailored interventions. Prioritizing high-SDI regions and focusing on vulnerable populations, especially women, are essential steps toward reducing disparities and alleviating the growing burden.

Moreover, the study exemplifies the power of robust epidemiological surveillance and advanced analytic techniques, such as joinpoint regression, in illuminating disease trajectories. These methods offer valuable tools for dynamically monitoring public health trends and informing evidence-based decision-making for mental health.

Ultimately, this extensive evaluation from the GBD 2021 provides a stark reminder of the unmet needs in mental health care and the imperative for global collaboration. Addressing these challenges demands multi-sectoral approaches encompassing policy reform, increased funding, research investment, and destigmatization efforts to foster environments where mental well-being can thrive.

As mental disorders continue to intensify in prevalence and impact, this pivotal research beckons the scientific community, health practitioners, and governments to urgently recalibrate priorities. Only through coordinated action anchored in rigorous data and nuanced understanding can the global burden of mental disorders be effectively tackled in the decades ahead.

Subject of Research: Global burden and trends of mental disorders across 204 countries and territories from 1990 to 2021, including the impact of COVID-19.

Article Title: Global burden of mental disorders in 204 countries and territories, 1990–2021: results from the global burden of disease study 2021

Article References:
Fan, Y., Fan, A., Yang, Z. et al. Global burden of mental disorders in 204 countries and territories, 1990–2021: results from the global burden of disease study 2021. BMC Psychiatry 25, 486 (2025). https://doi.org/10.1186/s12888-025-06932-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-06932-y